Precision Medicine in Severe Asthma: How Phenotypes and Endotypes Guide Treatment Decisions
  • CME
  • MOC

This activity will break down the differences between Type 2 and non-Type 2 asthma and discuss how making that differentiation in severe asthma patients has a profound impact on treatment pathways.
person default
Emily DiMango, MD
Michael E. Wechsler, MD, MMSc
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: September 13, 2019 Expiration: September 13, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the benefits and limitations of traditional asthma therapy (eg, ICS, LABAs, LAMAs, and LTRAs) for severe asthma phenotypes/endotypes.
  • Compare new and emerging phenotype/endotype-targeted agents for severe asthma.
  • Develop individualized treatment plans for patients with severe uncontrolled asthma.

Acknowledgements

Joint providership of the University of Cincinnati and MCM Education

ACCME Accreditation Support:
Please contact the University of Cincinnati Continuing Medical Education Department at uccme@uc.edu or call 513-558-7277

Supported by educational grants from
Sanofi Genzyme and Regeneron Pharmaceuticals
Novartis Pharmaceuticals Corporation

Information on this Educational Activity

Faculty

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director,
NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Hospital
Denver, Colorado

Dr. Wechsler discloses the following: Grants/Research Support: AstraZeneca, Teva, GlaxoSmithKline, Sanofi Genzyme Regeneron Consultant: AstraZeneca, Teva, GlaxoSmithKline, Sanofi Genzyme Regeneron, Genetech/Novartis
Emily DiMango, MD

Professor of Medicine
Director, John Edsall-John Wood Asthma Center
Columbia University Medical Center
New York, New York

Dr. DiMango discloses the following: Advisory Board: AstraZeneca

The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

The credit providers require all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.

Target Audience

Pulmonologists, allergists, primary care physicians (PCPs), NPs, PAs and other healthcare providers who manage patients with severe asthma.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation:

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification (from ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 MOC points. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

The American Academy of Physician Assistants, the American Association of Nurse Practitioners and the American Nurses Credentialing Center accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Program Medium

This program has been made available online.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?